You are not logged in.

Carboplatin dosing in ovarian cancer: problems and pitfalls

Collins, Ian M., Roberts-Thomson, Rachel, Faulkner, David, Rischin, Danny, Friedlander, Michael and Mileshkin, Linda 2011, Carboplatin dosing in ovarian cancer: problems and pitfalls, International journal of gynecological cancer, vol. 21, no. 7, pp. 1213-1218, doi: 10.1097/IGC.0b013e31822127ad.

Attached Files
Name Description MIMEType Size Downloads

Title Carboplatin dosing in ovarian cancer: problems and pitfalls
Author(s) Collins, Ian M.ORCID iD for Collins, Ian M. orcid.org/0000-0001-6936-0942
Roberts-Thomson, Rachel
Faulkner, David
Rischin, Danny
Friedlander, Michael
Mileshkin, Linda
Journal name International journal of gynecological cancer
Volume number 21
Issue number 7
Start page 1213
End page 1218
Total pages 6
Publisher Lippincott Williams & Wilkins
Place of publication London, Eng.
Publication date 2011-10
ISSN 1048-891X
1525-1438
Keyword(s) ovarian cancer
carboplatin
dosing
glomerular filtration rate
creatinine
Summary OBJECTIVE: Carboplatin is one of the most effective chemotherapeutic drugs for the treatment of ovarian cancer. It has simple pharmacokinetics and a predictable toxicity profile. The dose can be calculated effectively based on a patient's renal function as defined by the glomerular filtration rate (GFR). The measurement of the GFR is best done using radioisotopes, but this is expensive and not widely available, so many centers use equations to estimate GFR based on serum creatinine and other easily measured data. Recent changes in the measurement of serum creatinine, and a move toward isotope dilution mass spectrometry standardized values, have highlighted the difficulty in safely and effectively calculating doses of carboplatin in patients with ovarian cancer.
METHODS: We have evaluated the currently available evidence for the most common methods of estimating and measuring GFR. We explored the problems and pitfalls with using each of these methods or equations and examined the effects of small changes in clinical parameters and the effect on carboplatin dose.
RESULTS: Previous studies evaluating carboplatin's toxicity and efficacy used various different methods of GFR estimation and older methods of creatinine measurement. These may not translate to use with newer laboratory methods and may result in higher delivered doses than anticipated.
CONCLUSIONS: The lack of consistency in carboplatin dosing, and changing creatinine values are a cause for concern if patient toxicity is a possible outcome. The need for new studies using new standard methods that can be widely used are urgently required to provide clarity in this area.
Language eng
DOI 10.1097/IGC.0b013e31822127ad
Field of Research 111202 Cancer Diagnosis
1112 Oncology And Carcinogenesis
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2011, IGCS and ESGO
Persistent URL http://hdl.handle.net/10536/DRO/DU:30075053

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in TR Web of Science
Scopus Citation Count Cited 9 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 18 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 14 Aug 2015, 08:57:17 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.